About Holos

Our Company

holos_life_sciences_epigenetics_diagnostics_about_hero.jpg

About Holos

We are a life sciences company focused on the discovery and commercialisation of novel epigenetic biomarkers.

We utilise EpiSwitch™, an award winning, patented and clinically validated discovery system developed by our AIM listed shareholder Oxford Biodynamics Plc

Our unique application of EpiSwitch™ to non-disease state problems aims to develop biomarkers that enable the non-pharmaceutical enhancement of health, wellness and performance in humans and animals.

Our Science

As an integrator of multi-omic data, 3D genomics are powerful, predictive and prognostic indicators
3D genomics have the potential for broad commercial application such as use in preventative healthcare and diagnostics as well as performance and yield optimisation
EpiSwitch™ - a proprietary platform for the discovery of 3D genomics at scale - identifies chromosome conformation signature (CCS) biomarkers that are binary and stable, with both predictive and prognostic value
EpiSwitch™ has been utilised in trials by many of the world’s leading pharmaceutical companies with results published in leading peer-reviewed medical and scientific journals

Our Beliefs

To be truly preventative, health interventions need to be meaningfully personalised and actionable - requiring a whole-system multi-omic approach

By using EpiSwitch™ to continually measure the effect of biological, environmental and behavioural inputs on our epigenome, we can arrive at insights which are actionable, personal and precise

We believe that our biomarkers, based on EpiSwitch™ signatures, can be a critical component in developing the next generation of personalised healthcare and wellness outcomes for both humans and animals